Company Performance Metrics
- Juliette Hernando: Pharmaceutical Portfolio Analyst
- Emmanuel Piffo: President & CEO
Sorintellis is building the intelligence infrastructure for clinical drug development. Its mission is to D.O.P.E. the Pharma Pipeline — Design, Optimize, Prioritize, and Execute development programs with greater precision, transforming clinical development into a data-driven decision system. At the core of the platform is TrialsBank, a proprietary
expert-curated clinical drug development intelligence dataset developed over years to address the structural fragmentation of clinical development data across multiple sources and formats, coupled with the limited availability of high-quality, contextualized datasets.
Over the years, Sorintellis has built and validated TrialsBank — a one-of-a-kind, AI-ready, large-scale multimodal dataset integrating hundreds of thousands of deeply annotated, longitudinal Phase I–III clinical trials across all therapeutic areas. Enriched with scientific, clinical, operational, regulatory, and commercial features, TrialsBank powers advanced AI models that predict sequential, multi-level success (operational, scientific, phase transition, regulatory, and commercial) and enable trial design and execution optimization, real-time risk mitigation, asset valuation and prioritization, dynamic portfolio optimization, and capital allocation across the pharmaceutical R&D lifecycle.
Sorintellis collaborates with a strong ecosystem of leading industry and academic partners, including Pfizer, Mila – Quebec Artificial Intelligence Institute, IVADO, Université de Montréal, École Polytechnique de Montréal, PROMPT Québec, Mitacs, Université Laval, HEC-Montréal, CQDM, and CRO partners such as Vantage Biotrials.
The company is a finalist for the 2025 ADRIQ Artificial Intelligence Innovation Awards, a North American winner of HackerNoon’s Startup of the Year 2024, and has filed multiple international patent applications.
